Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Perlecan Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5100566
Description
Antibody detects endogenous levels of total HSPG2.
Perlecan is a major heparan-sulfate proteoglycan (HSPG) found within all basement membranes and cell surfaces. Because of its strategic location and ability to store and protect growth factors, perlecan has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a coreceptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment.
Specifications
Perlecan | |
Polyclonal | |
Unconjugated | |
HSPG2 | |
AI852380; Basement membrane-specific heparan sulfate proteoglycan core protein; Endorepellin; endorepellin (domain V region); heparan sulfate proteoglycan 2; HSPG; Hspg2; LG3 peptide; LOC313641; Pcn; per; perlecan; perlecan (heparan sulfate proteoglycan 2); perlecan proteoglycan; PLC; PRCAN; RP11-132G19.2; SJA; SJS; SJS1 | |
Rabbit | |
Affinity chromatography | |
RUO | |
15530, 313641, 3339 | |
-20°C | |
Liquid |
Western Blot | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
P98160, Q05793 | |
HSPG2 | |
A synthesized peptide derived from human HSPG2(Accession P98160), corresponding to amino acid residues E201-T251. | |
100 μL | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction